<?xml version="1.0" encoding="UTF-8"?>
<p id="Par28">Finally, although current treatment strategies for high-risk NB have resulted in improvement in response rates, long-term EFS and OS remain disappointing and many survivors have profound cumulative toxicities, including cardiotoxicity, ototoxicity, hypothyroidism, second malignancies and post-transplant complications that would limit further intensification of conventional therapy
 <sup>
  <xref ref-type="bibr" rid="CR31">31</xref>,
  <xref ref-type="bibr" rid="CR32">32</xref>
 </sup>. The schedule of maintenance DFMO utilized in the current trial appears to improve survival while demonstrating manageable toxicity. DFMO has been used for &gt;30 years by the World Health Organization for African sleeping sickness with a well-established safety profile. A prior phase I study in adults given doses of 3750 mg/m
 <sup>2</sup>/day—five times higher than the doses used in the current study—demonstrated no clinically significant renal, hepatic, auditory or hematologic toxicities
 <sup>
  <xref ref-type="bibr" rid="CR33">33</xref>
 </sup>.
</p>
